ERBB2 and cancer: Implementation of nanobody-based imaging of cancer markers can be a guide for therapy selection, in particular as targeted therapies have been developed for many of these cancer markers, some of which are based on the use of nanobodies, as exemplified by the use of anti-CD20 and anti-HER2 nanobodies for targeted therapy 94-96.